Tag: sacituzumab govitecan-hziy

Gilead gets Trodelvy FDA approval for pre-treated HR+/HER2- metastatic breast cancer

Raghuram Kadari- February 10, 2023

Gilead Sciences has secured the approval of the US Food and Drug Administration (FDA) for Trodelvy (sacituzumab govitecan-hziy) for pre-treated HR+/HER2- metastatic breast cancer. The ... Read More

Gilead gets Trodelvy FDA priority review for pre-treated HR+/HER2- metastatic breast cancer

businessnewstoday- October 16, 2022

Gilead Sciences said that Trodelvy (sacituzumab govitecan-hziy) has been granted priority review from the US Food and Drug Administration (FDA) for the treatment of another ... Read More

Gilead acquisition of Immunomedics : Pharma giant to gain access to breast cancer drug Trodelvy

pharmanewsdaily- September 14, 2020

Gilead acquisition of Immunomedics : US pharma giant Gilead Sciences has signed a $21 billion worth deal to acquire New Jersey-based biopharma company Immunomedics to ... Read More